Vytorin Sales Data
| Rank 89 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Vytorin U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 89 ( 9) |
$199,625 | -3.02% | 888 | -7.40% |
| Q3 2013 | 80 (8) |
$205,850 | -3.87% | 959 | -3.91% |
| Q2 2013 | 72 (1) |
$214,140 | -2.71% | 998 | -6.64% |
| Q1 2013 | 71 | $220,100 | -0.81% | 1,069 | -4.30% |
| Q4 2012 | 71 (6) |
$221,891 | -3.06% | 1,117 | -5.02% |
| Q3 2012 | 65 ( 6) |
$228,895 | 6.33% | 1,176 | -2.41% |
| Q2 2012 | 71 (4) |
$215,274 | -1.35% | 1,205 | -8.16% |
| Q1 2012 | 75 (4) |
$218,215 | -7.25% | 1,312 | -7.28% |
| Q4 2011 | 71 (10) |
$235,267 | -3.61% | 1,415 | -6.66% |
| Q3 2011 | 61 (7) |
$244,078 | -8.10% | 1,516 | -10.72% |
| Q2 2011 | 54 | $265,600 | -4.04% | 1,698 | -7.52% |
| Q1 2011 | 54 | $276,781 | n/a | 1,836 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
